Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

Giuseppina Novo, Alessia Pepe, Ines Monte, Christian Cadeddu Dessalvi, Alexander R. Lyon, Christian Cadeddu Dessalvi, Carlo Gabriele Tocchetti, Concetta Zito, Javid J Moslehi, Alessia Gimelli, Rosalinda Madonna, Giuseppe Mercuro, Donato Mele, Claudia Penna, Rudolf A De Boer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascular biomarkers and imaging techniques (echocardiography, magnetic resonance, and nuclear medicine) in the diagnosis and monitoring of cardiotoxicity, confirming that sex differences exist. The same is true about protective strategies from anthracycline cardiotoxicity. Indeed, first studied to withstand oxidative damage in response to ischemia/reperfusion (I/R) injury, cardioprotection has different outcomes in men and women. A number of studies assessed the differences in I/R response between male and female hearts, with oxidative stress and apoptosis being shared mechanisms between the I/R and anthracyclines heart damage. Sex hormones can modulate these mechanisms, thus confirming their importance in the pathophysiology in cardioprotection not only from the ischemia/reperfusion damage, but also from anthracyclines, fueling further cardio-oncologic research on the topic.
Original languageEnglish
Number of pages11
JournalHeart Failure Reviews
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens'. Together they form a unique fingerprint.

  • Cite this

    Novo, G., Pepe, A., Monte, I., Cadeddu Dessalvi, C., Lyon, A. R., Cadeddu Dessalvi, C., Tocchetti, C. G., Zito, C., Moslehi, J. J., Gimelli, A., Madonna, R., Mercuro, G., Mele, D., Penna, C., & De Boer, R. A. (2019). Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Failure Reviews.